Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last C$5.49 CAD
Change Today 0.00 / 0.00%
Volume 4.9K
As of 4:10 PM 08/28/15 All times are local (Market data is delayed by at least 15 minutes).

nuvo research inc (NRI) Snapshot

Open
C$5.49
Previous Close
C$5.49
Day High
C$5.50
Day Low
C$5.40
52 Week High
01/29/15 - C$10.38
52 Week Low
08/29/14 - C$3.26
Market Cap
59.9M
Average Volume 10 Days
27.1K
EPS TTM
C$0.45
Shares Outstanding
10.9M
EX-Date
--
P/E TM
12.2x
Dividend
--
Dividend Yield
--
Current Stock Chart for NUVO RESEARCH INC (NRI)

Related News

No related news articles were found.

nuvo research inc (NRI) Related Businessweek News

No Related Businessweek News Found

nuvo research inc (NRI) Details

Nuvo Research Inc., a specialty pharmaceutical company, researches, develops, and commercializes pharmaceutical products in Europe, Asia, and South America. The company has four commercialized products; a pipeline of topical and transdermal products focusing on various therapeutic areas, including pain and dermatology; and multiple drug delivery platforms that support the development of patented formulations that can deliver actives into or through the skin. Its topical pain products include Pennsaid, a non-steroidal anti-inflammatory drug that is used for the treatment of the pain of knee osteoarthritis; Pennsaid 2%, a follow-on product to Pennsaid for the treatment of pain of knee osteoarthritis; and Pliaglis, a topical local anaesthetic cream, which provides local dermal anaesthesia on intact skin prior to superficial dermatological procedures, such as dermal filler injection, pulsed dye laser therapy, facial laser resurfacing, and laser-assisted tattoo removal, as well as heated lidocaine/tetracaine patch, a topical patch that provides local dermal analgesia for superficial venous access and superficial dermatological procedures. The company’s immunology products comprise WF10, an immune system modulating drug containing chlorite and chlorate ions; and Oxoferin, a topical wound healing agent containing the active ingredient in WF10 at a lower concentration. The company was formerly known as Dimethaid Research Inc. and changed its name to Nuvo Research Inc. in September 2005. The company was founded in 1983 and is based in Mississauga, Canada.

72 Employees
Last Reported Date: 08/5/15
Founded in 1983

nuvo research inc (NRI) Top Compensated Officers

Co-Chief Executive Officer, President and Dir...
Total Annual Compensation: C$190.9K
Chairman and Co-Chief Executive Officer
Total Annual Compensation: C$190.9K
Chief Financial Officer and Vice President
Total Annual Compensation: C$260.0K
Director and President of Europe & Immunology...
Total Annual Compensation: C$343.8K
Vice President, General Counsel and Corporate...
Total Annual Compensation: C$245.0K
Compensation as of Fiscal Year 2014.

nuvo research inc (NRI) Key Developments

Nuvo Research Inc. Reports Revenue Results for the Second Quarter and Six Months Ended June 30, 2015

Nuvo Research Inc. reported revenue results for the second quarter and six months ended June 30, 2015. For the quarter, the company reported total revenue of CAD 3.25 million, compared to CAD 3.86 million for the second quarter ended June 30, 2014. For the six months, the company reported total revenue of CAD 7.79 million, compared to CAD 6.92 million for the six months ended June 30, 2014.

Nuvo Research Inc. Reports Consolidated Financial Results for the Second Quarter and Six Months Ended June 30, 2015; Provides Earnings Guidance for the Second Half of 2015

Nuvo Research Inc. reported consolidated financial results for the second quarter and six months ended June 30, 2015. For the quarter, the company reported product sales of CAD 2.914 million compared to CAD 2.205 million a year ago. Net loss was CAD 5.95 million or CAD 0.55 per basic and diluted share compared to operating income of CAD 2.31 million or CAD 0.23 per basic and diluted share a year ago. For the six months, the company reported product sales of CAD 6.817 million compared to CAD 3.361 million a year ago. Net loss was CAD 6.22 million or CAD 0.57 per basic and diluted share compared to operating income of CAD 5.05 million or CAD 0.53 per basic and diluted share a year ago. The company believes that the cash burn in the second half of the year, which will include approximately CAD 4.2 million of external R&D spending, will be consistent to that experienced in the first half of 2015, as it completes the trials for WF10 and Pennsaid 2%.

Nuvo Research Inc. to Report Q2, 2015 Results on Aug 05, 2015

Nuvo Research Inc. announced that they will report Q2, 2015 results After-Market on Aug 05, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NRI:CN C$5.49 CAD 0.00

NRI Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Endo International PLC $78.70 USD -0.30
Novartis AG SFr.94.20 CHF -0.15
View Industry Companies
 

Industry Analysis

NRI

Industry Average

Valuation NRI Industry Range
Price/Earnings 1.5x
Price/Sales 4.0x
Price/Book 1.1x
Price/Cash Flow 1.5x
TEV/Sales 0.3x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NUVO RESEARCH INC, please visit www.nuvoresearch.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.